Meeting
2016 ASCO Annual Meeting
Efficacy and safety of triplet versus doublet salvage therapies among relapsed myeloma patients: Meta-analysis of phase 3 randomized controlled trials.
Authors
Ajay K. Nooka
Emory University Winship Cancer Center, Atlanta, GA
Ajay K. Nooka , Jonathan L. Kaufman , Sagar Lonial
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 34, 2016 (suppl; abstr 8020)
DOI
10.1200/JCO.2016.34.15_suppl.8020
Abstract #
8020
Poster Bd #
285
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Comparative efficacy of multiple myeloma therapies for treatment of first relapse: A systematic literature review and network meta-analysis.
First Author: Eric M Maiese
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of zolbetuximab for CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials.
First Author: Davi Said Gonçalves Celso
Poster
2023 ASCO Annual Meeting
Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study.
First Author: Thierry Facon
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of frontline systemic therapy for advanced hepatocellular carcinoma (aHCC): A network meta-analysis of landmark phase III trials.
First Author: Claudia A.M. Fulgenzi